SHANGHAI, CHINA--(MARKET WIRE)--Jul 10, 2007 -- Sinobiomed Inc. (“Sinobiomed”, or “the Company”) (OTC BB:SOBM.OB - News) is pleased to update on clinical trial progress for the recombinant batroxobin (rBAT) made by Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. (“Shanghai Wanxing”), the Company’s 82% owned subsidiary.
